Expression of EGFR-mutant proteins and genomic evolution in EGFR-mutant transformed small cell lung cancer
نویسندگان
چکیده
Background: The transformation of epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma (LUAD) into small cell cancer (SCLC) accounts for 3–14% the resistance mechanism to EGFR tyrosine kinase inhibitors (TKIs). At present, there is no relevant research explore dynamic expression EGFR-mutant proteins and genomic evolution in transformed SCLC/neuroendocrine carcinoma (NEC).
منابع مشابه
EGFR mutant lung cancer.
Thoracic oncologists traditionally have made treatment decisions based upon tumor histology, distinguishing non-small cell lung cancer (NSCLC) from small cell lung cancer (SCLC). However, recent data has revealed that at least one histological subtype of NSCLC, lung adenocarcinoma comprises multiple molecularly distinct diseases. Lung adenocarcinoma subsets now can be defined by specific 'drive...
متن کاملRB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer
Tyrosine kinase inhibitors are effective treatments for non-small-cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) mutations. However, relapse typically occurs after an average of 1 year of continuous treatment. A fundamental histological transformation from NSCLC to small-cell lung cancer (SCLC) is observed in a subset of the resistant cancers, but the molecular changes ...
متن کاملmiRNAs and resistance to EGFR—TKIs in EGFR-mutant non-small cell lung cancer: beyond ‘traditional mechanisms’ of resistance
Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) have dramatically changed the prognosis of advanced non-small cell lung cancers (NSCLCs) that harbour specific EGFR activating mutations. However, the efficacy of an EGFR-TKI is limited by the onset of acquired resistance, usually within one year, in virtually all treated patients. Moreover, a small percentage of EGFR-mut...
متن کاملTAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells
TAE226, a bis-anilino pyrimidine compound, has been developed as an inhibitor of focal adhesion kinase (FAK) and insulin-like growth factor-I receptor (IGF-IR). In this study, we investigated the effect of TAE226 on non-small-cell lung cancer (NSCLC), especially focusing on the EGFR mutational status. TAE226 was more effective against cells with mutant EGFR, including the T790M mutant, than aga...
متن کاملChmielecki with Evolutionary Cancer Modeling Small Cell Lung Cancer − Optimization of Dosing for EGFR - Mutant Non
strategies. models based on the characteristics of diverse cancer cell types could offer clues for designing optimal treatment utility of evolutionary mathematical modeling in designing cancer treatments. If they prove beneficial, individual will have to come from patients. Clinical trials based on these alternative dosing strategies will be the true test of the resistance to prevent fast overg...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Thoracic Disease
سال: 2023
ISSN: ['2077-6624', '2072-1439']
DOI: https://doi.org/10.21037/jtd-23-161